Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan-High Solid Tumors

NCT02563548 is registered in ClinicalTrials.gov with Halozyme Therapeutics as lead sponsor.

NCT NCT02563548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02563548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan-High Solid Tumors
Lead sponsor
Halozyme Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
October 22, 2015
Completion date
March 26, 2019
Enrollment
56 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, nsclc